Global TB Diagnostic Market 2015-2019
About TB Diagnostics
TB is an infectious bacterial disease caused by Mycobacterium tuberculosis. It is communicable and can be transmitted from one person to another. TB is one of the world’s deadliest communicable diseases. In 2013, there were 9 million new TB cases and 1.5 million TB deaths, out of which 1.1 million among HIV-negative people and 0.4 million among HIV-positive people.
The symptoms of active TB of the lung include coughing, occasionally with sputum or blood, weakness, chest pains, weight loss, fever, and night sweats. Though the disease is preventive in developed countries, there is a shortage of efficient diagnosis tools and detection in developing countries.
Technavio’s analysts forecast the global TB diagnostic market to grow at a CAGR of 2.97% during the period 2014-2019.
Covered in this Report
The report covers the present scenario and the growth prospects of the global TB diagnostic market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of TB diagnostic products in the market.
Technavio's report, Global TB Diagnostic Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the global TB diagnostics market landscape and its growth prospects over the coming years. The report includes a discussion of the key vendors operating in this market.Key Geographies
Technavio recognizes the following companies as the key players in the Global TB Diagnostic Market: Abbott, Alere, Becton, Dickinson, and Co. and Roche Diagnostics
Other Prominent Vendors in the market are: Siemens, BioMérieux, Cepheid, Hain Lifescience, Hologic, Ortho Clinical, Epistem, Eiken Chemical and Alere US
Commenting on the report, an analyst from Technavio’s team said: “Developments in the diagnostic paradigm and increased allocation of funds and resources have led to the manufacture of new technologies for TB diagnosis. These innovative technologies help to make disease diagnosis rapid and accurate. For instance, the WHO recommends Xpert MTB/RIF for disease diagnosis as the equipment provides improved accuracy and test sensitivity. In 2013, rapid tests were used to diagnose TB in 58% of the 4.9 million individuals with pulmonary TB. Various non-profit organizations are now funding high-burden low-income countries to use these rapid tests. High- and moderate-burden countries, such as South Africa and Brazil, have also intensified their research on molecular diagnostics to develop rapid tests.”
According to the report, the WHO identifies 22 nations, including India, China, and South Africa, as high-burden countries. The high prevalence of the disease has increased the demand for early diagnosis and detection tools. Many countries implement innovative strategies to address market needs, such as public awareness programs and the launch of fast, accurate, and early diagnostics, resulting in a decline in disease incidence rates.
Further, the report states that diagnosing infection and drug-resistant TB is a major factor hindering the market growth.
Abbott, Alere, Becton, Dickinson, F. Hoffmann-La Roche, Siemens, BioMérieux, Cepheid, Hain Lifescience, Hologic, Ortho Clinical, Epistem UK, Eiken Chemical Japan, Alere US
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook